L-citrulline Blood Flow Randomized Trial: What the Evidence Says

Quick Answer

L-citrulline Blood Flow Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 randomized trial, 1 research article.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Background: Post-COVID-19 syndrome is associated with endothelial dysfunction (ED) and various sequelae, particularly in individuals who experienced critical illness during the acute phase, affecting lung function and the musculoskeletal system. [Fernanda SM (2026); evidence level 2]
• Conclusions: L-citrulline supplementation for three months decreased ICAM-1 and increased 6MWT. [Fernanda SM (2026); evidence level 2]
• Through its involvement in NO-related pathways, L-ARG supplementation has been associated with changes in vascular function and blood flow, which may influence exercise-related physiological responses (,-). [Uçar Halil (2026); evidence level 4]
• However, the findings across these studies remain inconsistent, and conclusive evidence supporting clear performance or recovery benefits has yet to be established. [Uçar Halil (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For l-citrulline blood flow randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Fernanda SM (2026). Effect of L-Citrulline Supplementation on Endothelial Function and Body Composition in Post-COVID-19 Syndrome: A Randomized Clinical Trial.. DOI: 10.3390/nu18111706. PMCID: PMC13258655. PMID: 42280350. https://pmc.ncbi.nlm.nih.gov/articles/PMC13258655/
• Uçar Halil (2026). Acute effects of citrulline malate and L-arginine, alone and in combination, on anaerobic performance indicators in highly trained taekwondo athletes. DOI: 10.3389/fnut.2026.1788549. PMCID: PMC13057471. PMID: 41958907. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13057471/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.